Chester County News and Community Website
PLYMOUTH MEETING, PA — A nationwide clinical trial found that cancer patients who followed a structured exercise program during chemotherapy reported fewer problems with thinking and memory, according to research …
Study Finds Exercise May Reduce Cognitive Effects During Chemotherapy Read More
PHILADELPHIA, PA — Century Therapeutics Inc. (Nasdaq: IPSC) reported its financial results for 2025 and outlined progress across its pipeline of stem cell-derived therapies, including plans to submit a regulatory …
Century Therapeutics Reports 2025 Results, Advances Cell Therapy Pipeline Read More
PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) reported additional data from its Phase 2 SKNJCT-003 clinical study evaluating the SkinJect microneedle delivery system for the treatment of basal cell …
Medicus Reports Phase 2 Results for SkinJect Basal Cell Carcinoma Study Read More
HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and Drug Administration has approved TECVAYLI (teclistamab-cqyv) in combination with DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) for adults …
FDA Approves TECVAYLI and DARZALEX FASPRO Combo for Multiple Myeloma Read More
PLYMOUTH MEETING, PA — INOVIO and Akeso, Inc. announced a clinical trial collaboration to evaluate a combination immunotherapy as a potential treatment for Glioblastoma, the most common and aggressive form …
INOVIO and Akeso Partner to Study New Glioblastoma Therapy Read More
PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) reported topline results from a Phase 2 clinical trial evaluating its Doxorubicin Microneedle Array treatment for basal cell carcinoma of the skin.
Medicus Pharma Reports Phase 2 Results for Basal Cell Carcinoma Therapy Read More
PHILADELPHIA, PA — Passage Bio, Inc. (Nasdaq: PASG) reported fourth-quarter and full-year 2025 financial results while providing updates on its clinical program studying PBFT02, a gene therapy candidate for genetic …
Passage Bio Advances Frontotemporal Dementia Trial and Reports 2025 Results Read More
MALVERN, PA — Ocugen, Inc. (Nasdaq: OCGN) announced it has completed enrollment for the Phase 3 liMeliGhT clinical trial evaluating OCU400, a gene therapy candidate for retinitis pigmentosa, a group …
Ocugen Completes Enrollment for Phase 3 Trial of OCU400 Gene Therapy Read More
BERWYN, PA — Mural Health announced it has expanded global payment capabilities within its Mural Link participant management platform to enable local payments to clinical trial participants in multiple countries.
Mural Health Expands Clinical Trial Participant Payment Capabilities Read More
CONSHOHOCKEN, PA — Suvoda announced the addition of split budget functionality to its Budgeting & Benchmarking software, a tool used by sponsors and contract research organizations to develop and manage …
Suvoda Adds Split Budget Feature to Clinical Trial Budgeting Software Read More